Photo of Jerry Chapman, Principal, Quality Data & Analytics at Redica

Jerry Chapman

Principal, Quality Data & Analytics

Conference Spotlight

Japan’s PMDA Formalizing Post-Approval Change System Based on Recent Pilot

October 26, 2022
Conference Spotlight

Senior Management Failures Lead to Patient Deaths, Prison Sentence

October 25, 2022
Conference Spotlight

Post-Approval Change Management Protocol Pilot Aims to Reduce Approval Time

October 19, 2022
Conference Spotlight

Navigating Drug Approvals and Post-Approval Changes in the Asia-Pacific Region

October 11, 2022

Why am I Being Inspected Again So Soon After a Pre-Approval Inspection?

October 6, 2022
Conference Spotlight

How To Get Drug Products Approved In Asia-Pacific Markets

October 5, 2022
Conference Spotlight

Who Decides if my FDA Inspection is Classified OAI?

September 29, 2022
Conference Spotlight

Getting Drugs Approved in Mexico, Argentina, Colombia, And Peru

September 27, 2022
Conference Spotlight

How to Get New Drugs Approved in Brazil

September 21, 2022

Where is My EIR?

September 20, 2022
Conference Spotlight

FDA on Compliance Issues in Pharma

September 16, 2022
Conference Spotlight

CMC Challenges and Opportunities in Latin America

September 13, 2022
Conference Spotlight

An FDA Perspective on Decentralized Clinical Trials: Part III

August 11, 2022
Conference Spotlight

An FDA Perspective on Decentralized Clinical Trials: Part II

August 4, 2022
Conference Spotlight

An FDA Perspective on Decentralized Clinical Trials: Part I

July 28, 2022
Conference Spotlight

Five FDA Warning Letters Issued in Four Years for Fraudulent Cancer Drug

July 14, 2022
Conference Spotlight

Extracting Specific Protocol Violations from Warning Letter Citations

June 23, 2022
Conference Spotlight

FDA Issues First Notices of Noncompliance on ClinicalTrials.Gov

June 16, 2022